Psoriasis

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.

Black race and male sex increased odds of palmoplantar psoriasis among pediatric patients, according to a study.

After 1 year of continuous use, risankizumab helped patients with moderate to severe plaque psoriasis achieve skin clearance regardless of prior biologic usage, according to a real-world study.

Patients with psoriasis are at an increased risk for experiencing asymptomatic coronary microvascular dysfunction and should be actively evaluated for risk factors by dermatologists, according to a study.

SAN DIEGO — Patient age and disease-related factors may be driving safety signals in medications used to treat rheumatoid arthritis and psoriatic disease, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more.

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.

Evelo Biosciences announced that it has accumulated enough financial resources to take its psoriasis drug candidate past the phase 2 clinical readout, according to the company’s second-quarter 2023 financial results.

Based on results from a phase 1b trial, SFA-002 improved the signs and symptoms of chronic plaque psoriasis in patients within 6 weeks, SFA Therapeutics announced in a press release.

Arcutis announced its financial results for the second quarter of 2023, which included a total revenue of $5.2 million and a 72% increase in Zoryve revenue, according to a company press release.